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Abstract
Background: Kidney transplantation is considered to be the treatment of choice for people with end-stage renal
disease (ESRD). However, due to the shortage of available organs and the increase in the ESRD prevalence in
Europe, it is essential to improve transplantation outcomes by studying the related prognostic factors. Today, there
is no European registry collecting data to perform such clinical epidemiology studies.
Main body: Entitled EKiTE, for European cohort for Kidney Transplantation Epidemiology, this prospective and
multicentric cohort includes patients from Spanish (Barcelona), Belgian (Leuven), Norwegian (Oslo) and French (Paris
Necker, Lyon, Nantes, Nancy, Montpellier, Nice and Paris Saint Louis) transplantation centers and currently contains 13,
394 adult recipients of kidney (only) transplantation from 2005 and updated annually. A large set of parameters
collected from transplantation until graft failure or death with numbers of post-transplantation outcomes. The long-
term follow-up and the collected data enable a wide range of possible survival and longitudinal analyses.
Conclusion: EKiTE is a multicentric cohort aiming to better assess the natural history of the ESRD in European kidney
transplant recipients and perform benchmarking of clinical practices. The data are available for clinical epidemiology
studies and open for external investigators upon request to the scientific council. Short-term perspectives are to extend
EKITE network to other European countries and collect additional parameters in respect of the common thesaurus.
Keywords: European database, Kidney transplantation, Cohort, Epidemiology
Background
In 2016, the European prevalence of End Stage Renal
Disease (ESRD) was assessed at 1160 patients per million
inhabitants [1]. In many countries, this number is con-
stantly increasing due to the aging population and the
increasing prevalence of cardiovascular and metabolic
diseases. Fortunately, in several developed countries,
including Western Europe, the incidence of ESRD re-
cently stabilized. Nevertheless, the life expectancy of
ESRD patients has even increased, resulting in an in-
crease in the ESRD prevalence, a challenge in terms of
costs and capacity for health care systems in Europe [2].
Kidney transplantation is considered as the treatment of
choice for people with ESRD, because of increased quality
of life [3, 4], better chances of survival [5, 6] and lower
costs compared to long term dialysis [7, 8]. However, the
number of available donor kidneys is not sufficient to
meet the demand [9]. One solution is to improve graft
survival and to avoid or minimize returns to dialysis and
hence better utilize the available organs. For many years,
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one of the major achievements of clinical and scientific
transplantation science has been to decipher the causes of
graft rejection and loss and significant improvements have
been made. Current ongoing efforts are particularly
focused on improving organ failure risk prediction and on
identifying the more efficient treatments in real-life set-
tings. Reaching these objectives requires contemporary
and high-quality datasets for large cohorts of kidney trans-
plant recipients.
Whilst there are already International and National
transplantation registries, such as the Heidelberg-based
Collaborative Transplant Study [1], the US Scientific Regis-
try of Transplant Recipients [3, 4] and the ANZDATA
registry in Australia and New Zealand [5, 6], no European
renal transplantation database exists to enable more precise
epidemiology studies, such as Coemans et al. [10]. A
European-focused clinical epidemiology study could also
help to identify and understand differences in patient care
between countries, as recently stated by the European Kid-
ney Health Alliance (EKHA) in their call to improve kidney
care in Europe [8].
In this context, we propose a novel cohort entitled
“EKiTE” for European cohort for Kidney Transplantation
Epidemiology for facilitating European epidemiological
studies. It aims to i) provide a better understanding of
the evolution of kidney transplant patients, ii) support
European guidelines for management of kidney trans-
plant patients (ERBP, European Renal Best Practice), iii)
provide data for development or validation of predictive
tools, and iv) to support epidemiology studies on rare
patient’s profiles or infrequent complications.
In this manuscript, we present the EKiTE cohort by
detailing its design and the process for any external re-
searcher requesting access to the data. We also describe
its demographic characteristics and provide examples of




The EKiTE cohort was set up to combine into a single
European cohort all incident adult kidney (only) trans-
plant recipients since 2005 and updated annually. Only
patients with negative crossmatches at the time of sur-
gery were included. To date, the data are collected from
existing databases from 4 countries: 1) the Spanish
monocentric cohort of Bellvitge University Hospital
Transplant Registry in Barcelona (n = 840), 2) the
Belgium monocentric cohort of Biobank Renal Trans-
plantation of the University Hospitals Leuven (n = 1684),
3) the French multicentric DIVAT cohort (Données
Informatisées et Validées en Transplantation, n = 8433)
based on 7 transplantation centers (Paris Necker, Lyon,
Nantes, Nancy, Montpellier, Nice, Paris Saint Louis),
and 4) the Norwegian Renal Registry of the University
Hospital of Oslo (which performs all Norwegian kidney
transplantations, n = 2437).
Follow-up
Patients are followed until death or graft failure (i.e. defini-
tive return to dialysis or pre-emptive re-transplantation).
For patients alive at the time of the data importation, the
maximum follow-up time corresponds to the time be-
tween the surgery and the last date for which we know
that the recipient is alive with a functioning graft. All
patients are informed of the data collection and give in-
formed consent, if required by the national or local ethical
committee.
Data collection
As mentioned above, individual patient data entered into
the EKiTE database has already been collected in the
participating centers and therefore data collecting proce-
dures currently performed according to local practices
are unchanged. We voluntarily limited data collection to
44 informative parameters related to kidney recipients
and donors that we considered essential to perform epi-
demiologic analyses. The data are listed in Table 1 along
with their common definition in the EKiTE thesaurus.
Data circuit and production software
The principal investigator or the data manager from each
local cohort extracts annually the required parameters
from their own local database using a standard .csv elec-
tronic format and uploads it into the EKiTE data ware-
house using an original software program specifically
developed by the IDBC Company (www.idbc.fr). The
principle is to automatically convert the parameters into a
common coding system according to the EKiTE thesaurus
(Table 1) and control the correctness of the uploaded
data. As illustrated in Fig. 1, a report of incorrect data is
produced when databases are uploaded, such that correc-
tions can be made in the original cohort. This process al-
lows to considerably limiting outliers and incoherent data.
Data are stored in the EKiTE data warehouse using an Or-
acle platform designed to meet the highest security stan-
dards and are accessible via a secure Windows 2008 Web
Server hosted by the company IDBC/A2COM (with the
French label for data hosting, Hébergeur de Santé).
Data coding
For each patient a unique identification key is generated
for the EKiTE database. Only the principal investigator
from the center in which the patient was transplanted
can make the correspondence between the EKiTE key
and to the original cohort key. To ensure that patients
cannot be identified in any way, dates are converted to a
corresponding time post-transplantation. Overall, the
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Table 1 List of variables included in EKiTE
Variable Definition
Variables related to the
recipient of the surgery
Year of transplantation Calendar year of the current transplantation
Recipient gender Gender of the recipient
Recipient age Recipient age in years at transplantation
Recipient height Recipient height in centimeters at transplantation
Recipient weight Recipient weight in kilograms at transplantation
Duration under renal
replacement therapy
Number of days between the first dialysis (hemodialysis and/or peritoneal
dialysis) or the first preemptive transplantation and the transplantation
Duration on waiting list
before the transplantation
Number of days between the registration on the waiting list related to the
current transplantation and the transplantation
Type of dialysis just before
the transplantation
Type of extra renal purification technique just before the transplantation
Primary renal disease Primary cause of renal failure
Vascular history Whether the recipient had a history of vascular disease before transplantation
Cardiac history Whether the recipient had a cardiovascular history before transplantation
Cancer history Whether the recipient had cancer before transplantation
Diabetes history Whether the recipient had diabetes before transplantation
Hepatitis history Whether the recipient had hepatitis B or C before transplantation
Recipient CMV serology Result of the last recipient cytomegalovirus serology before transplantation
Recipient EBV serology Result of the last recipient Epstein-Barr virus serology before transplantation
Anti-class I Immunization Whether anti-HLA (Human Leukocyte Antigen) class I antibodies were detected
during the 6 months before transplantation
Anti-class II Immunization Whether anti-HLA (Human Leukocyte Antigen) class II antibodies were detected
during the 6 months before transplantation
Recipient HIV serology Result of the last recipient human immunodeficiency virus serology before
transplantation
Recipient blood group Blood group of the recipient
Induction therapy Type of induction therapy at transplantation
Variables related to donor
at surgery
Age at the graft retrieval Donor age in years at kidney retrieval
Donor gender Gender of the donor
Type of donor Whether the transplant came from a living or deceased donor
Type of deceased donation Heart-beating status for the deceased donations
Donor cause of death Indication of the cerebrovascular cause of death of the donor
Last donor serum creatinine Last serum creatinine level in μmol. L− 1 of the donor before graft retrieval
Donor CMV serology Result of the last cytomegalovirus serology of the donor before graft retrieval
Donor EBV serology Result of the last Epstein-Barr virus serology of the donor before graft retrieval
Donor blood group Blood group of the donor
Variables related to
transplantation at surgery
Cold ischemia time Time in minutes between the graft retrieval and its reperfusion, the warm
ischemia time being excluded
Number of HLA-A
mismatches
Number of mismatches between the donor and the recipient concerning
Human Leukocyte Antigen Locus A (HLA-A)
Number of HLA-B
mismatches
Number of mismatches between the donor and the recipient concerning
Human Leukocyte Antigen Locus B (HLA-B)
Number of HLA-DR
mismatches
Number of mismatches between the donor and the recipient concerning
Human Leukocyte Antigen Locus DR (HLA-DR)




Recipient weight Recipient weight in kilograms at 3 months and 6 months post-transplantation,
and at each anniversary of the transplantation
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included data exclude any information that might dir-
ectly or indirectly identify a patient.
Quality control
The quality of data is verified respecting each cohort
local procedures. Missing data is closely monitored, and
it is strongly encouraged that the data are retrieved if
possible using a list of base variables that is pre-specified
by the Scientific Committee. Inspection or audit by
health authorities may take place. The coordinator and/
or participating centers must be able to provide data ac-
cess to inspectors or auditors.
Regulatory aspects
A consortium agreement has been written and approved
by the Directors of each University Hospital participating
in the EKiTE network. It stipulates the specific and
mandatory rules for a common networking. Collected data
are stored in a computer system respecting the French law
on Information technology and civil liberties (January 6th
1978, amended in April 29th 2004). The protocol received
authorization from the CCTIRS (Comité Consultatif sur le
Traitement de l’Information en matière de Recherche dans
le domaine de la Santé) as well as the CNIL in December
2017 (Commission Nationale de l’Informatique et des
Libertés, N°917155).
Data extraction procedure and software
Each center has the right to login to the database to ac-
cess their own data (using a personal username and
password). Data from other centers is not accessible.
The network manager is the only person with access to
all data using a personal username and password.
The Plug-Stat® software developed by the common
laboratory in Research in Informatics and Statistics for
Cohort-based Analyses (LabCom RISCA, www.labcom-
risca.com/plug-stat) is an internet-accessible application
running on the main web browsers. It allows to select a
sample of patients according to inclusion criteria and
then to perform various queries such as counting the
number of patients, extracting the data, comparing the
distribution of a variable between two exposure groups
(i.e. two sub-groups of patients among the patients re-
specting the inclusion criteria), computing and plotting
various statistical indicators (means, proportions and
survival curves). Beside these usual descriptive methods,
Plug-stat® also allows taking into consideration the main
difficulties of long-term observational studies: confound-
ing factors, competing events and longitudinal markers.
The results are directly exploitable for publication in
international peer review journals.
Via Plug-Stat®, each center has the right to login to the
database to access their own data (using a personal user-
name and password). Data from the other centers is not
accessible, except for a particular authorization by the net-
work manager and the scientific council for a particular
multicentric study. The network manager is the only per-
son with a permanent access to all data and is in charge of
setting up the different authorization for extracting the data
and for authorizing the mono or multi-centric accesses.
Governance and working rules of the network
Governance
The network is regulated by the following personnel: one
scientific coordinator, one database administrator, four sci-
entific managers (one per country), and one methodologist/





Maintenance immunosuppressive drug prescribed at 3 months and 6months
post-transplantation, and at each anniversary of the transplantation. In case of
switching, the most recent treatment is indicated. 7 treatments may be
indicated: calcineurin inhibitor, mycophenolate mofetil, mycophenolic acid,
azathioprine, sirolimus, everolimus and steroids
Recipient serum creatinine Recipient serum creatinine level in μmol. L−1 at 3 months and 6months post-
transplantation, and at each anniversary of the transplantation
Recipient daily proteinuria Recipient proteinuria in g.L−1 at 3 months and 6months post-transplantation,
and at each anniversary of the transplantation
Delayed graft function The need for at least one dialysis session within the first 7 days post-
transplantation
Time-to-death Time in days between the surgery and the patient’s death with a functioning
graft (death after return-to-dialysis is not considered)




Time in days between the surgery and the first acute rejection episode
Maximum follow-up time Time in days between the surgery and the last known date at which the
recipient was alive with a functioning graft
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biostatistician. The Steering committee is composed of the
coordinator and the four managers. The steering commit-
tee members meet once per year to plan the Network’s ac-
tivities, to implement the database and to validate the
quality procedures. The scientific committee is composed
of the coordinator, the four scientific managers and four
statisticians/epidemiologists (one per country). Scientific
Committee members meet once per year to approve scien-
tific projects and discuss various strategic decisions.
Publication rules
Any publications that make use of the EKiTE data from
one or several centers must cite the center initiating the
study, and all the centers involved in the study. Author
positions in the publication are attributed according to the
scientific involvement of each center. All co-authors are
supposed to read and approve the initial study protocol
and the final version of the manuscript before publication.
Any publication/communication must mention the
EKiTE Network and relevant financial support (institu-
tional or private). Finally, any publication/communica-
tion must mention in the acknowledgments all the
research staff involved in the network (data managers,
statisticians, clinical research associates, etc.).
Open data rules
Each participating investigator has the right to login (using
a personal username and password) to the data of his own
Fig. 1 Flowchart of data collection process
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center. A participating or a third (meaning external to the
EKiTE network) investigator may request access to the
database to perform a scientific project. In this case, a pro-
ject proposal is sent by mail (magali.giral@chu-nantes.fr)
to the Scientific Committee of the network. If the project
is approved by the Scientific Committee, and thereafter by
the relevant local ethics committees of centers whose data
is used, the study is definitively approved and the study
can start, as illustrated in Fig. 2. In the case of non-
approval of the project by the Scientific Committee or one
of the ethics committees, a modified study proposal can
be submitted.
In case of approval for a participating investigator, she/he
receives a study ID and password with which she/he can
login to the database via the software Plug-Stat®. This gives
access to the data from the other centers. The data can be
analyzed directly using Plug-Stat® or can be downloaded to
perform analysis using an external statistical software. For a
third investigator, she/he will receive an electronic extrac-
tion of the database in .csv format, including the data from
the requested centers that fulfill the requested inclusion
and exclusion criteria.
The network manager will be the sole person which
has access to all data using a personal username and
password. In any case, data are only shared in a way
such that their confidentiality are preserved.
Utility and discussion
Description of the cohort at baseline
At present a total of 13,394 kidney transplantations be-
tween 2005 and 2018 are included in EKiTE. The demo-
graphics and baseline characteristics of recipients and
donors at the time of transplantation are presented in
Table 2. The mean recipient age was 52.3 (± 14.0) years
Fig. 2 Flowchart of data access procedure
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and 63.5% were male. History of vascular disease, cardiac
disease, diabetes and cancer concerned respectively 14.9,
24.6, 17.4, and 11.9% of the recipients before transplant-
ation. 17.6% of the transplants were repeat transplantation
after failure of a previous graft. 16.2% of the transplanta-
tions were pre-emptive, prior to initiation of dialysis. Im-
munologic characteristics included: 23.9, 39.7 and 13.8%
of patients presenting more than 1 HLA–A, −B or -DR in-
compatibility respectively, 36.0% were immunized against
class I HLA antigens prior to transplantation and 32.5%
against class II. The mean cold ischemia time was 11.0
(± 10.3) hours, and glomerulonephritis was diagnosed as
initial nephropathy in 27.9% of the recipients. Donors
were mainly deceased (81.5%) with a mean age of 52.1
(± 15.8) years and 54.8% were male. The mean last donor
serum creatinine was 84.8 (± 50.3) μmol. L− 1 and cause of
death was cerebrovascular damage in 46.5%.
Description of the outcomes
The median follow-up time was 4.1 years (range from 0.0
to 13.3). Delayed Graft Function (DGF) occurred in 2703
Table 2 Description of the EKiTE cohort (N = 13,394)
Continuous variables: mean ± sd Missing data Total cohort
Categorical variables: number (%) N (%) (N = 13,394)
TRANSPLANTATION
Year of transplantation > 2010 – – 7894 (58.9%)
Rank of the graft ≥2 – – 2353 (17.6%)
Cold ischemia time (min) 151 (1.1) 661.3 ±618.6
HLA-A mismatches > 1 549 (4.1) 3075 (23.9%)
HLA-B mismatches > 1 314 (2.3) 5188 (39.7%)
HLA-DR mismatches > 1 402 (3.0) 1799 (13.8%)
RECIPIENT
Male gender – – 8500 (63.5%)
Age (years) – – 52.3 ±14.0
Height (centimeters) 935 (7.0) 169.6 ±9.8
Weight (kilograms) 1290 (9.6) 72.0 ±15.4
Dialysis (years) 368 (2.7) 3.4 ±4.6
Duration on waiting list (years) 3649 (27.2) 2.0 ±2.0
Type of dialysis
No dialysis 29 (0.2) 2159 (16.2%)
Hemodialysis 9580 (71.7%)
Peritoneal dialysis 1626 (12.2%)
Primary renal disease
Glomerulonephritis 1910 (14.3) 3200 (27.9%)
Tubulo interstitial disease 4035 (35.1%)
Reno-vascular disease 1054 (9.2%)
Diabetes 1075 (9.4%)
Other disease and unknown 2120 (18.5%)
Vascular history 33 (0.2) 1992 (14.9%)
Cardiac history 96 (0.7) 3267 (24.6%)
Diabetes history – – 2325 (17.4%)
Cancer history 5 (0.0) 1595 (11.9%)
Positive CMV serology 332 (2.5) 8722 (66.8%)
Positive EBV serology 5041 (37.6) 8096 (96.9%)
Positive HIV serology 1801 (13.4) 129 (1.1%)
Positive anti-class I HLA antibodies 2838 (21.2) 3797 (36.0%)
Positive anti-class II HLA antibodies 2967 (22.2) 3388 (32.5%)
Blood group









Table 2 Description of the EKiTE cohort (N = 13,394) (Continued)
Continuous variables: mean ± sd Missing data Total cohort
Categorical variables: number (%) N (%) (N = 13,394)
Other 853 (6.4%)
Delayed Graft Function 1727 (12.9) 2703 (23.2%)
DONOR
Age at retrieval (years) 148 (1.1) 52.1 ±15.8
Male gender 111 (0.8) 7283 (54.8%)
Type of donor
Deceased 74 (0.6) 10,855 (81.5%)
Living 2465 (18.5%)
Type of deceased donor
Heart beating 12 (0.1) 10,278 (76.8%)
Non-heart-beating 635 (4.7%)
Non-attributable 2469 (18.5%)
Donor cause of death
Cerebrovascular 171 (1.3) 6146 (46.5%)
Other 4608 (34.8%)
Non-attributable 2469 (18.7%)
Last donor serum creatinine (μmol/L) 2119 (15.8) 84.8 ±50.3
Positive CMV serology 135 (1.0) 7720 (58.2)
Positive EBV serology 4428 (33.1) 8518 (95.0%)
Blood group
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patients (23.2%). The mean recipient serum creatinine was
139.2 (± 56.8) μmol. L− 1 at 3months post-transplantation,
139.1 (± 55.6) μmol. L− 1 at 6months and 138.3 (± 55.8)
μmol. L− 1 at 1 year. Approximately 6.3% had a 1-year pro-
teinuria higher than 1 g/24 h. Finally, 16.2% of the recipients
presented at least one episode of acute rejection (ARE) be-
fore the first anniversary of the graft.
Several survival curves and their corresponding 95% con-
fidence interval (95% CI) are presented in Fig. 3 (Kaplan-
Meier estimator). At 10 years post-transplantation, 1637
recipients returned to dialysis, 1396 died with a functioning
graft and 1122 remained alive. Patient-graft survival at 10
years after the transplantation was 58.1% [95% CI 56.7%;
59.6%]. The corresponding patient and death censored graft
survival were 76.2% [95% CI 74.9%; 77.6%] and 76.3% [95%
CI 75.0%; 77.6%] respectively. Finally, acute rejection
episode-free survival at 2-years post-transplantation was
79.0% [95% CI 78.5%; 79.6%].
Examples of future scientific projects
A project that will be performed soon is the external
validation of several prognostic scores in kidney
transplantation, notably those developed by the DIVAT-
SPHERE group in Nantes:
 The Kidney Transplant Failure Score (KTFS) [11]
is a composite score, taking into account a series
of eight well-accepted pre- and post-transplant
risk factors of graft loss, which evaluates the risk
of graft failure up to 8 years post transplantation.
The clinical utility of the KTFS is currently under
study in a randomized clinical trial (national
PHRC 2011 - TELEGRAFT, clinicaltrials.gov:
NCT01615900) [12]. The objective is to demonstrate
the efficiency of personalized care according to the
KTFS.
 The Delayed Graft Function Score (DGFS) [13] is a
simple composite score to classify patients according
to their DGF (Delayed Graft Function) risk at the
time of transplantation and to thus propose
individualized management or therapeutic strategies.
The clinical utility of the DGFS is currently under
study in a randomized clinical trial (national PHRC
2013 – PREDICT-DGF, clinicaltrials.gov:
NCT02056938) [14]. The aim is to evaluate the
Fig. 3 Survival curves according to the time of transplantation (n = 13,394) from Kaplan-Meier estimator (black lines) and their corresponding 95%
CI (dotted lines). a Patient-graft survival; b Patient survival (with a functioning graft); c Graft survival (with death-censored); d Rejection
free survival
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effectiveness of ATG (Anti Thymocyte Globulins) for
preventing DGF in patients with low immunologic
risk and high risk of DGF, in comparison with
Simulect treatment.
 The 1-year Recipient Risk Score (RRS) [15] includes five
pre- and post-transplant variables and is intended to
predict mortality after the first year of transplantation.
The integration of the 1-year RRS in the TELEGRAFT
clinical trial could be complementary to the KTFS. This
would allow adapting patient care according to the risk
of death and the risk of graft loss.
These scores seem to be robust, since; i) they were de-
veloped on the basis of high-quality data, ii) they are
based on adapted statistical modeling, and iii) they are
validated on independent data. The external validation
(European patients) of these scores is essential to evalu-
ate their applicability outside of France and for an inter-
national recognition of these studies.
An important objective of EKiTE is to allow access to
the data warehouse to support projects by internal or ex-
ternal teams. The following studies could be performed:
the comparison of baseline characteristics of trans-
planted patients between the 4 countries, assessment of
the disparity in treatments and prescriptions between
the 4 countries, the study of the determinants of the net
survival, i.e. the survival when the only possible deaths
are related to ESRD [16], and the role of the organ do-
nor’s last serum creatinine level prior to retrieval in the
prognosis of recipient and graft survivals.
Limits of the collected data
For the first step in the construction of the EKiTE cohort,
we have chosen to limit the number of collected data that
are not subject to discussion or clinical interpretation. It is
made mainly with general characteristics of the trans-
plantation, the donor and the recipient at the time of the
surgery and some of them during the post-transplantation
period. Additional data such as type of rejection (cellular
or antibody mediated), biopsy findings or de novo anti
HLA immunization (in particular donor specific) will be
useful for future epidemiological studies. A perspective of
the network will be to work progressively to increase the
number and the precision of the collected parameters.
However, since several centers that participate to the
EKITE cohort [17] do not practice surveillance biopsies it
makes difficult to enter pathology findings on the data-
base. Concerning DSA immunization, it was not possible
to retrospectively collect this parameter. Nevertheless, be-
cause DSA are now routinely diagnosed at the time of
transplantation and at each anniversary of the transplant-
ation in all participating centers of the EKITE cohort, it
would be possible in a next step to collect this parameter
for incident kidney transplant recipients from 2020, with
also anti HLA specificity and MFI.
Conclusion
EKiTE is a novel, large European multinational cohort
with a large amount of baseline data from the recent
era of kidney transplantation that is updated annually
and has a low level of missing data. It will allow epide-
miologic studies to be performed to better assess the
western European transplantation patient profile and
allow benchmarking to improve clinical practices.
Other European centers are invited to join the EKiTE
network. For details on the process of inclusion of a
new center you can take note of the “Consortium
Agreement for the EKiTE network” (provided in
Additional file 1) or make contact with a network
member at the following address www.labcom-risca.
com/ekite-en. External investigators of the EKiTE net-
work, are also welcome to ask for access to this open
database for scientific works.
Additional file
Additional file 1: Consortium Agreement for the EKiTE network.
(DOCX 501 kb)
Abbreviations
ANZDATA: Australia and New Zealand Dialysis and Transplant Registry;
ARE: Acute Rejection Episode; CCTIRS: Comité Consultatif sur le Traitement
de l’Information en matière de Recherche dans le domaine de la Santé;
CI: Confidence Interval; CMV: Cytomegalovirus; CNIL: Commission Nationale
Informatique et Libertés; DGF: Delayed Graft Function; DIVAT: Données
Informatisées et VAlidées en Transplantation; DSA: Donor Specific Antibodies;
EBV: Epstein Barr Virus; EKHA: European Kidney Health Alliance;
EKiTE: Epidemiology in Kidney Transplantation - a European validated
database; ERBP: European Renal Best Practice; ESRD: End Stage Renal Disease;
HIV: Human Immunodeficiency Virus; HLA: Human Leukocyte Antigen;
MFI: Mean Fluorescence Intensity; RISCA: Research in Informatics and
Statistics for Cohort-based Analyses; sd: Standard Deviation
Acknowledgments
Authors thank the EKiTE consortium: OSLO (Anna V Reisæter, Pål-Dag Line,
Anders Åsberg), Leuven (Dirk Kuypers, Pieter Evenepoel, Kathleen Claes, Bert
Bammens, Ben Sprangers, Maarten Naesens, Björn Meijers, Katrien De Vusser,
Amaryllis Van Craenenbroeck, Evelyne Lerut), Barcelone (Oriol Bestard
Matamoros, Nuria Montero, Salvador Gil-Vernet, Edoardo Melilli) and DIVAT
cohort (Nantes: Gilles Blancho, Julien Branchereau, Diego Cantarovich, Agnès
Chapelet, Jacques Dantal, Clément Deltombe, Lucile Figueres, Claire
Garandeau, Magali Giral, Caroline Gourraud-Vercel, Maryvonne Hourmant,
Georges Karam, Clarisse Kerleau, Aurélie Meurette, Simon Ville, Christine
Kandell, Anne Moreau, Karine Renaudin, Anne Cesbron, Florent Delbos,
Alexandre Walencik, Anne Devis; Paris-Necker: Lucile Amrouche, Dany
Anglicheau, Olivier Aubert, Lynda Bererhi, Christophe Legendre, Alexandre
Loupy, Frank Martinez, Rébecca Sberro-Soussan, Anne Scemla, Claire Tinel,
Julien Zuber; Nancy: Pascal Eschwege, Luc Frimat, Sophie Girerd, Jacques
Hubert, Marc Ladriere, Emmanuelle Laurain, Louis Leblanc, Pierre Lecoanet,
Jean-Louis Lemelle; Lyon E. Hériot: Lionel Badet, Maria Brunet, Fanny Buron,
Rémi Cahen, Sameh Daoud, Coralie Fournie, Arnaud Grégoire, Alice Koenig,
Charlène Lévi, Emmanuel Morelon, Claire Pouteil-Noble, Thomas Rimmelé,
Olivier Thaunat; Montpellier: Sylvie Delmas, Valérie Garrigue, Moglie Le
Quintrec, Vincent Pernin, Jean-Emmanuel Serre).
Authors also thank the IDBC company for the EKiTE data warehouse
development.
Lorent et al. BMC Nephrology          (2019) 20:365 Page 9 of 10
Authors’ contributions
YF, SB, MN, OBM, AA, and MG have made substantial contributions to the
conception and design of the EKiTE Network. ML, CL, CB, MN, OBM, AA, and
MG have contributed to the acquisition of data. ML analyzed the data. ML,
YF and MG interpreted the results. ML, YF and MG drafted the work or
substantively revised it. All authors have read and approved the submitted
version and agreed to be accountable for all aspects of the work in ensuring
that questions related to the accuracy or integrity of any part of the work
are appropriately investigated and resolved.
Funding
The design of the study, the collection, analysis, and interpretation of the
data and also the writing manuscript was funded by a grant from Nantes
University Hospital “AOI 2015 - RC15_0419” obtained in 2015.
The software of the EKITE cohort and the statistics were supported by a
public grant overseen by the French National Research Agency (ANR-16-
LCV1–0003-01) to implement the Plug-Stat®.
Availability of data and materials
The EKITE database analyzed during the current study were obtained from 4
existing datasets: the Spanish monocentric cohort of Bellvitge University
Hospital Transplant Registry in Barcelona, 2) the Belgium monocentric cohort
of Biobank Renal Transplantation of the University Hospitals Leuven, 3) the
French multicenter DIVAT cohort (www.divat.fr) and 4) the Norwegian Renal
Registry of the University Hospital of Oslo. There is public access to the
database available from the corresponding author on reasonable request
and restricted to the approval of the scientific committee of the EKITE
consortium and thereafter by the relevant local ethics committees of centers
whose data is used. The EKITE database received administrative permission
to access and to use these datasets.
Ethics approval and consent to participate
The EKiTE network received authorization the 12/14/2017 (N°917155) from
the ethics committee “Comité Consultatif sur le Traitement de l’Information
en matière de Recherche dans le domaine de la Santé” (CCTIRS) for the
cohort entitled: “Etude portant sur l’épidémiologie dans la transplantation
rénale en Europe”, intitulée “EKITE”, as well as from the “Commission
Nationale de l’Informatique et des Libertés” (CNIL) in Decembre 2017.
Preliminary informed and written consent are obtained from patients




The authors declare that they have conflicts of interest with Sanofi and
Novartis.
Sanofi and Novartis Laboratories helped for supporting part of the
development of the Common computerized Data Warehouse to initiate the
EKITE cohort since 2015.
Author details
1CRTI UMR 1064, Inserm, Université de Nantes; ITUN, CHU Nantes; RTRS
Centaure, Nantes, France. 2INSERM UMR 1246 – SPHERE, Nantes University,
Tours University, Nantes, France. 3Centre Hospitalier Universitaire de Nantes,
Nantes, France. 4LabCom RISCA (Recherche en Informatique et en Statistique
pour l’Analyse de Cohortes), Nantes, France. 5Centre d’Investigation Clinique
(CIC) en Biotherapie, CHU Nantes, Nantes, France. 6Department of Microbiology,
Immunology and Transplantation, KU Leuven, Department of Nephrology,
University Hospitals Leuven, Leuven, Belgium. 7Nephrology department, Bellvitge
University Hospital, Barcelona, Spain. 8Department of Transplantation Medicine,
Oslo University Hospital; Department of Pharmacy, University of Oslo, Oslo,
Norway. 9Inserm Center of Clinic Investigation and Biotherapy, Hôtel Dieu
University Hospital, 30, bd Jean Monnet, 44093 Nantes Cedex 01, France.
Received: 7 June 2019 Accepted: 14 August 2019
References
1. European Renal Care Providers Association. Facts & Figures 2016. http://
ercpa.eu/facts-figures/ (Accessed 6 Sept 2016).
2. Wetmore JB, Collins AJ. Global challenges posed by the growth of end-
stage renal disease. Ren Replace Ther. 2016;2:15. https://doi.org/10.1186/
s41100-016-0021-7.
3. Cameron J, Whiteside C, Katz J, Devins GM. Differences in quality of life
across renal replacement therapies: a meta-analytic comparison. Am J
Kidney Dis. 2000;35:629–37. https://doi.org/10.1016/S0272-6386(00)70009-6.
4. Tonelli M, Wiebe N, Knoll G, Bello A, Browne S, Jadhav D, et al. Systematic
review: kidney transplantation compared with dialysis in clinically relevant
outcomes. Am J Transplant. 2011;11:2093–109. https://doi.org/10.1111/j.16
00-6143.2011.03686.x.
5. Ojo AO, Hanson JA, Wolfe RA, Leichtman AB, Agodoa LY, Port FK. Long-
term survival in renal transplant recipients with graft function. Kidney Int.
2000;57:307–13. https://doi.org/10.1046/j.1523-1755.2000.00816.x.
6. Wolfe RA, Ashby VB, Milford EL, Ojo AO, Ettenger RE, Agodoa LY, et al.
Comparison of mortality in all patients on dialysis, patients on dialysis
awaiting transplantation, and recipients of a first cadaveric transplant. N
Engl J Med. 1999;341:1725–30. https://doi.org/10.1056/NEJM199912
023412303.
7. Laupacis A, Keown P, Pus N, Krueger H, Ferguson B, Wong C, et al. A study
of the quality of life and cost-utility of renal transplantation. Kidney Int.
1996;50:235–42. https://doi.org/10.1038/ki.1996.307.
8. EKHA. The alarming rise in chronic kidney disease in Europe: how to deal
with this costly problem. 2013.
9. ABM. Reseau Epidemiologie Information Néphrologie. 2016.
10. Coemans M, Susal C, Dohler B, Anglicheau D, Giral M, Bestard O, et al.
Analyses of the short- and long-term graft survival after kidney
transplantation in Europe between 1986 and 2015. Kidney Int. 2018;94:
964–73. https://doi.org/10.1016/j.kint.2018.05.018.
11. Foucher Y, Daguin P, Akl A, Kessler M, Ladrière M, Legendre C, et al. A
clinical scoring system highly predictive of long-term kidney graft survival.
Kidney Int. 2010;78:1288–94. https://doi.org/10.1038/ki.2010.232.
12. Foucher Y, Meurette A, Daguin P, Bonnaud-Antignac A, Hardouin J-B,
Chailan S, et al. A personalized follow-up of kidney transplant
recipients using video conferencing based on a 1-year scoring system
predictive of long term graft failure (TELEGRAFT study): protocol for a
randomized controlled trial. BMC Nephrol. 2015;16:6. https://doi.org/1
0.1186/1471-2369-16-6.
13. Chapal M, Le Borgne F, Legendre C, Kreis H, Mourad G, Garrigue V, et al. A
useful scoring system for the prediction and management of delayed graft
function following kidney transplantation from cadaveric donors. Kidney Int.
2014;86:1130–9. https://doi.org/10.1038/ki.2014.188.
14. Chapal M, Foucher Y, Marguerite M, Neau K, Papuchon E, Daguin P, et al.
PREventing delayed graft function by driving immunosuppressive InduCtion
treatment (PREDICT-DGF): study protocol for a randomized controlled trial.
Trials. 2015;16:282. https://doi.org/10.1186/s13063-015-0807-x.
15. Lorent M, Giral M, Pascual M, Koller MT, Steiger J. Mortality Prediction
after the First Year of Kidney Transplantation : An Observational Study
on Two European Cohorts; 2016. p. 1–15. https://doi.org/10.1371/journal.
pone.0155278.
16. Perme MP, Stare J, Estève J. On estimation in relative survival. Biometrics.
2012;68:113–20. https://doi.org/10.1111/j.1541-0420.2011.01640.x.
17. Couvrat-Desvergnes G, Foucher Y, Le Borgne F, Dion A, Mourad G, Garrigue
V, et al. Comparison of graft and patient survival according to the
transplantation Centre policy for 1-year screening biopsy among stable
kidney recipients: a propensity score-based study. Nephrol Dial Transplant
Off Publ Eur Dial Transpl Assoc - Eur Ren Assoc. 2019;34:703–11. https://doi.
org/10.1093/ndt/gfy221.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Lorent et al. BMC Nephrology          (2019) 20:365 Page 10 of 10
